“RenBiologics” Collaboration Expands Rapidly, Providing Efficient Options for Novel Drug Development
– total disclosed deal value exceeds billions of dollars.
“RenBiologics”, a scaled antibody drug discovery program utilizing Biocytogen’s proprietary RenMice® technology platform, has reached significant milestones since its launch in March 2020. By July 2023, RenBiologics had acquired a library of over 400,000 off-the-shelf antibody molecules and 40+ PCC molecules. These assets have greatly accelerated the preclinical drug development timeline and enhanced the efficiency of translational medical research. Biocytogen employs an open and flexible business model that fosters resource-sharing with global partners, sparking a period of rapid growth in external collaborations. Our technology platforms, antibodies, and ADC molecules have been accredited by numerous pharmaceutical and biotechnology companies, including multinational corporations (MNCs), with partners spanning Asia-Pacific, Europe, and the United States. The disclosed transaction value currently stands in the billions of dollars. In addition to upfront payments, Biocytogen will receive R&D or commercialization milestone payments as our partners progress in their R&D efforts.
Antibody-drug conjugates (ADCs) have revolutionized targeted therapies due to their unique advantages. Biocytogen’s proprietary common light chain platform, RenLite®, and the innovative linker & payload platform, BLD1102, have demonstrated significant advantages in developing bispecific ADC drugs. Following the early 2024 licensing agreement with Radiance for YH012 (a HER2 x TROP2 bispecific ADC), we have established collaborations with ABL Bio, SOTIO, and IDEAYA in the bispecific ADC field. “RenBiologics” has developed a comprehensive library of antibodies targeting 200+ tumor-associated antigens (TAA), providing robust support for multiple ADC companies in developing the next generation of differentiated ADC therapies.
Biocytogen’s collaborations in the ADC field (partial list)
“RenBiologics” has generated a library of more than 400,000 fully human antibody molecules. These assets are applicable not only to drug discovery in the ADC field but also to the treatment development targeting innovative markers such as GPCRs, and new modalities including cell therapies and bispecific/multispecific antibodies. This comprehensive library supports drug development across various disease areas, including neurology, autoimmunity, metabolism, and infectious diseases. Renowned for its high diversity and affinity, our fully human antibody library has established extensive collaborations with MNCs such as Gilead and Merck KGaA, as well as innovative pharmaceutical companies like Neurocrine and Hansoh Pharma, covering a wide range of drug formats and therapeutic areas.
Biocytogen’s collaborations in antibody molecules (partial list)
In addition, Biocytogen’s TCR-mimic antibodies, derived from its proprietary RenTCR-mimicTM platform, excel at recognizing intracellular target antigens with greater specificity and affinity compared to endogenous human TCRs. These antibodies are well-suited for further development into T-cell engagers, bispecific/multispecific antibodies, as well as TCR-T and CAR-T cell therapies. Leveraging this technology, Biocytogen has forged collaborations with companies such as CtM Bio, Fineimmune, and BioCopy from Switzerland. Notably, our partnership with CtM Bio on the development of the WT1 x CD3 x 4-1BB multispecific antibody has reached significant milestones.
Biocytogen’s collaborations in TCR-mimic antibodies.
We have granted our selected antibody assets to our partners to advance clinical trials. The agreement for YH008/NWY001 (a PD-1 × CD40 bispecific antibody) in Greater China has been granted to Chengdu Chipscreen NewWay Biosciences. The initial subject enrollment for Phase I clinical trials has been completed, and the trials are progressing smoothly. Additionally, our global agreements for clinical-stage assets—YH001 (a CTLA-4 monoclonal antibody), YH003 (a CD40 agonist monoclonal antibody), and YH002 (an OX40 monoclonal antibody)—have been granted to Syncromune. This collaboration underpins the development and commercialization of intratumoral immunotherapy leveraging SYNC-T technology. Notably, SV-102 has achieved an objective response rate (ORR) of 85% in Phase I trials and has garnered FDA Fast Track designation. The successful progression of these clinical trials fully affirms the viability of Biocytogen’s large-scale in vivo antibody screening method.
Biocytogen’s collaborations in clinical-stage assets.
Biocytogen’s proprietary series of fully human antibody/TCR RenMice platforms—RenMab®, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™— form the foundation of the successful “RenBiologics” program. These platforms robustly support the development of fully human monoclonal antibodies, bispecific antibodies, bispecific ADCs, nanobodies, fully human TCRs, and TCR-mimic antibodies. As of December 31, 2023, Biocytogen has issued RenMice licenses for 47 target projects to leading global partners, including Merck KGaA, Janssen (a Johnson & Johnson company), Xencor, BeiGene, and Junshi Biosciences.
Overview of Biocytogen’s antibody assets available for collaborations.
Biocytogen’s state-of-the-art technology platforms and off-the-shelf antibody molecule libraries provide global partners with efficient solutions for developing novel therapies. The continuous production of high-quality antibodies from the “RenBiologics” program has significantly accelerated our international expansion. We believe that, through our collaborative efforts with partners, we will continue to deliver more effective and safer innovative therapies to patients worldwide. This initiative not only expands the reach of Biocytogen’s antibodies globally but also advances our vision of becoming the leading source of new drugs.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/ RenLite®/ RenNano®/ RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
